Comprehensive Phenotype/Genotype Analyses of the Norepinephrine Transporter Gene (SLC6A2) in ADHD: Relation to Maternal Smoking during Pregnancy

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Thakur, Geeta A ^a,b   Sengupta, Sarojini M ^b   Grizenko, Natalie ^a,b   Choudhry, Zia ^a,b   Joober, Ridha ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; NORADRENALIN TRANSPORTER; PLACEBO;

ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIORAL SCIENCE; CHILD; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DSM-IV; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATERNAL SMOKING; MORNING DOSAGE; PHENOTYPE; PLANNING; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SLC6A2 GENE; SPATIAL MEMORY; TREATMENT RESPONSE; WORKING MEMORY;

ALLELES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD BEHAVIOR; COGNITION; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MATERNAL EXPOSURE; METHYLPHENIDATE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PHENOTYPE; PLACEBOS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; SMOKING;

EID: 84869855996     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049616     Document Type: Article

References (84)

1. Willcutt EG, (2012) The Prevalence of DSM-IV Attention-Deficit/Hyperactivity Disorder: A Meta-Analytic Review. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics 9: 490-499.
2. Biederman J, Faraone SV, (2005) Attention-deficit hyperactivity disorder. Lancet 366: 237-248.
3. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, et al. (2005) Molecular genetics of attention-deficit/hyperactivity disorder. Biological psychiatry 57: 1313-1323.
4. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, et al. (2002) Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry 41: 26S-49S.
5. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K, (2000) Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neuroscience letters 285: 107-110.
6. Madras BK, Miller GM, Fischman AJ, (2005) The dopamine transporter and attention-deficit/hyperactivity disorder. Biological psychiatry 57: 1397-1409.
7. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, et al. (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. The Journal of neuroscience: the official journal of the Society for Neuroscience 21: RC121.
8. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J, (2004) Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. Journal of clinical psychopharmacology 24: 24-29.
9. Biederman J, Spencer T, (2002) Methylphenidate in treatment of adults with Attention-Deficit/Hyperactivity Disorder. Journal of attention disorders 6Suppl 1: S101-107.
10. Hanna GL, Ornitz EM, Hariharan M, (1996) Urinary catecholamine excretion and behavioral differences in ADHD and normal boys. Journal of child and adolescent psychopharmacology 6: 63-73.
11. Shekim WO, Javaid J, Davis JM, Bylund DB, (1983) Urinary MHPG and HVA excretion in boys with attention deficit disorder and hyperactivity treated with d-amphetamine. Biological psychiatry 18: 707-714.
12. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW, (2011) The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biological psychiatry 69: e145-157.
13. Arnsten AF, Pliszka SR, (2011) Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacology, biochemistry, and behavior 99: 211-216.
14. Uhl GR, Johnson PS, (1994) Neurotransmitter transporters: three important gene families for neuronal function. The Journal of experimental biology 196: 229-236.
15. Bruss M, Kunz J, Lingen B, Bonisch H, (1993) Chromosomal mapping of the human gene for the tricyclic antidepressant-sensitive noradrenaline transporter. Human genetics 91: 278-280.
16. Porzgen P, Bonisch H, Bruss M, (1995) Molecular cloning and organization of the coding region of the human norepinephrine transporter gene. Biochemical and biophysical research communications 215: 1145-1150.
17. Pacholczyk T, Blakely RD, Amara SG, (1991) Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350: 350-354.
18. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, et al. (2004) Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. American journal of human genetics 75: 807-821.
19. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, et al. (1996) Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6: 243-250.
20. Barr CL, Kroft J, Feng Y, Wigg K, Roberts W, et al. (2002) The norepinephrine transporter gene and attention-deficit hyperactivity disorder. American journal of medical genetics 114: 255-259.
21. Biederman J, Kim JW, Doyle AE, Mick E, Fagerness J, et al. (2008) Sexually dimorphic effects of four genes (COMT, SLC6A2, MAOA, SLC6A4) in genetic associations of ADHD: a preliminary study. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 147B: 1511-1518.
22. Bobb AJ, Addington AM, Sidransky E, Gornick MC, Lerch JP, et al. (2005) Support for association between ADHD and two candidate genes: NET1 and DRD1. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 134B: 67-72.
23. Brookes K, Xu X, Chen W, Zhou K, Neale B, et al. (2006) The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Molecular psychiatry 11: 934-953.
24. Cho SC, Kim JW, Kim BN, Hwang JW, Park M, et al. (2008) No evidence of an association between norepinephrine transporter gene polymorphisms and attention deficit hyperactivity disorder: a family-based and case-control association study in a Korean sample. Neuropsychobiology 57: 131-138.
25. De Luca V, Muglia P, Jain U, Kennedy JL, (2004) No evidence of linkage or association between the norepinephrine transporter (NET) gene MnlI polymorphism and adult ADHD. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 124B: 38-40.
26. Kim JW, Biederman J, McGrath CL, Doyle AE, Mick E, et al. (2008) Further evidence of association between two NET single-nucleotide polymorphisms with ADHD. Molecular psychiatry 13: 624-630.
27. McEvoy B, Hawi Z, Fitzgerald M, Gill M, (2002) No evidence of linkage or association between the norepinephrine transporter (NET) gene polymorphisms and ADHD in the Irish population. American journal of medical genetics 114: 665-666.
28. Renner TJ, Nguyen TT, Romanos M, Walitza S, Roser C, et al. (2011) No evidence for association between a functional promoter variant of the Norepinephrine Transporter gene SLC6A2 and ADHD in a family-based sample. Attention deficit and hyperactivity disorders 3: 285-289.
29. Xu X, Hawi Z, Brookes KJ, Anney R, Bellgrove M, et al. (2008) Replication of a rare protective allele in the noradrenaline transporter gene and ADHD. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 147B: 1564-1567.
30. Xu X, Knight J, Brookes K, Mill J, Sham P, et al. (2005) DNA pooling analysis of 21 norepinephrine transporter gene SNPs with attention deficit hyperactivity disorder: no evidence for association. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 134B: 115-118.
31. Joung Y, Kim CH, Moon J, Jang WS, Yang J, et al. (2010) Association studies of-3081(A/T) polymorphism of norepinephrine transporter gene with attention deficit/hyperactivity disorder in Korean population. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 153B: 691-694.
32. Kim CH, Hahn MK, Joung Y, Anderson SL, Steele AH, et al. (2006) A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proceedings of the National Academy of Sciences of the United States of America 103: 19164-19169.
33. Kim CH, Waldman ID, Blakely RD, Kim KS, (2008) Functional gene variation in the human norepinephrine transporter: association with attention deficit hyperactivity disorder. Annals of the New York Academy of Sciences 1129: 256-260.
34. Kollins SH, Anastopoulos AD, Lachiewicz AM, FitzGerald D, Morrissey-Kane E, et al. (2008) SNPs in dopamine D2 receptor gene (DRD2) and norepinephrine transporter gene (NET) are associated with continuous performance task (CPT) phenotypes in ADHD children and their families. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 147B: 1580-1588.
35. Song DH, Jhung K, Song J, Cheon KA, (2011) The 1287 G/A polymorphism of the norepinephrine transporter gene (NET) is involved in commission errors in Korean children with attention deficit hyperactivity disorder. Behavioral and brain functions: BBF 7: 12.
36. Retz W, Rosler M, Kissling C, Wiemann S, Hunnerkopf R, et al. (2008) Norepinephrine transporter and catecholamine-O-methyltransferase gene variants and attention-deficit/hyperactivity disorder symptoms in adults. Journal of neural transmission 115: 323-329.
37. Mick E, Neale B, Middleton FA, McGough JJ, Faraone SV, (2008) Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 147B: 1412-1418.
38. Kim BN, Kim JW, Hong SB, Cho SC, Shin MS, et al. (2010) Possible association of norepinephrine transporter-3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder. Behavioral and brain functions: BBF 6: 57.
39. Song J, Song DH, Jhung K, Cheon KA, (2011) Norepinephrine transporter gene (SLC6A2) is involved with methylphenidate response in Korean children with attention deficit hyperactivity disorder. International clinical psychopharmacology 26: 107-113.
40. Yang L, Wang YF, Li J, Faraone SV, (2004) Association of norepinephrine transporter gene with methylphenidate response. Journal of the American Academy of Child and Adolescent Psychiatry 43: 1154-1158.
41. Cho SC, Kim BN, Cummins TD, Kim JW, Bellgrove MA (2011) Norepinephrine transporter-3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment. Journal of psychopharmacology.
42. Lee SH, Kim SW, Lee MG, Yook KH, Greenhill LL, et al. (2011) Lack of association between response of OROS-methylphenidate and norepinephrine transporter (SLC6A2) polymorphism in Korean ADHD. Psychiatry research 186: 338-344.
43. Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS, (1995) Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. Journal of substance abuse 7: 373-378.
44. Langley K, Rice F, van den Bree MB, Thapar A, (2005) Maternal smoking during pregnancy as an environmental risk factor for attention deficit hyperactivity disorder behaviour. A review. Minerva pediatrica 57: 359-371.
45. McClernon FJ, Kollins SH, (2008) ADHD and smoking: from genes to brain to behavior. Annals of the New York Academy of Sciences 1141: 131-147.
46. Grizenko N, Kovacina B, Amor LB, Schwartz G, Ter-Stepanian M, et al. (2006) Relationship between response to methylphenidate treatment in children with ADHD and psychopathology in their families. Journal of the American Academy of Child and Adolescent Psychiatry 45: 47-53.
47. Sengupta SM, Grizenko N, Thakur GA, Bellingham J, DeGuzman R, et al. (2012) Differential association between the norepinephrine transporter gene and ADHD: role of sex and subtype. Journal of psychiatry & neuroscience: JPN 37: 129-137.
48. Conners CK, Sitarenios G, Parker JD, Epstein JN, (1998) Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity. Journal of abnormal child psychology 26: 279-291.
49. Conners CK, Sitarenios G, Parker JD, Epstein JN, (1998) The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. Journal of abnormal child psychology 26: 257-268.
50. Hudziak JJ, Derks EM, Althoff RR, Rettew DC, Boomsma DI, (2005) The genetic and environmental contributions to attention deficit hyperactivity disorder as measured by the Conners' Rating Scales-Revised. The American journal of psychiatry 162: 1614-1620.
51. Achenbach TM (1991) The child behaviour checklist/4-18. Burlington: University of Vermont.
52. Mitsis EM, McKay KE, Schulz KP, Newcorn JH, Halperin JM, (2000) Parent-teacher concordance for DSM-IV attention-deficit/hyperactivity disorder in a clinic-referred sample. Journal of the American Academy of Child and Adolescent Psychiatry 39: 308-313.
53. Thapar A, Langley K, O'Donovan M, Owen M, (2006) Refining the attention deficit hyperactivity disorder phenotype for molecular genetic studies. Molecular psychiatry 11: 714-720.
54. Touliatos J, Lindholm BW, (1981) Congruence of parents' and teachers' ratings of children's behavior problems. Journal of abnormal child psychology 9: 347-354.
55. Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF, (2005) Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biological psychiatry 57: 1336-1346.
56. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G (1993) The Wisconsin Card Sorting Test Manual-Revised and expanded. Odessa, FL: Psychological Assessment Resources.
57. Shallice T, (1982) Specific impairments of planning. Philosophical transactions of the Royal Society of London Series B, Biological sciences 298: 199-209.
58. Petrides M, Milner B, (1982) Deficits on subject-ordered tasks after frontal- and temporal-lobe lesions in man. Neuropsychologia 20: 249-262.
59. Conners CK (1995) Conners continuous performance test computer program. Toronto, Ontario: Multi-Health Systems.
60. Sheslow D, Adams W (1990) Wide Range Assessment of Memory and Learning: Administration Manual. Wilmington, DE: Jastak.
61. Gruber R, Grizenko N, Schwartz G, Bellingham J, Guzman R, et al. (2007) Performance on the continuous performance test in children with ADHD is associated with sleep efficiency. Sleep 30: 1003-1009.
62. Taerk E, Grizenko N, Ben Amor L, Lageix P, Mbekou V, et al. (2004) Catechol-O-methyltransferase (COMT) Val108/158 Met polymorphism does not modulate executive function in children with ADHD. BMC medical genetics 5: 30.
63. Kebir O, Tabbane K, Sengupta S, Joober R, (2009) Candidate genes and neuropsychological phenotypes in children with ADHD: review of association studies. Journal of psychiatry & neuroscience: JPN 34: 88-101.
64. Weschler D (1991) Weschler Intellingence Scale for Children-Third Edition: Manual. San Antonio, TX: Psychological Corporation.
65. Barkley RA (1990) Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment. New York: Guilford Press.
66. Fischer M, Newby RF, (1998) Use of the restricted academic task in ADHD dose-response relationships. Journal of learning disabilities 31: 608-612.
67. Sengupta S, Grizenko N, Schmitz N, Schwartz G, Bellingham J, et al. (2008) COMT Val108/158Met polymorphism and the modulation of task-oriented behavior in children with ADHD. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 33: 3069-3077.
68. Karama S, Ben Amor L, Grizenko N, Ciampi A, Mbekou V, et al. (2009) Factor structure of the restricted academic situation scale: implications for ADHD. Journal of attention disorders 12: 442-448.
69. Ehrich M, Bocker S, van den Boom D, (2005) Multiplexed discovery of sequence polymorphisms using base-specific cleavage and MALDI-TOF MS. Nucleic acids research 33: e38.
70. Stephens M, Smith NJ, Donnelly P, (2001) A new statistical method for haplotype reconstruction from population data. American journal of human genetics 68: 978-989.
71. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, et al. (2002) The structure of haplotype blocks in the human genome. Science 296: 2225-2229.
72. Horvath S, Xu X, Laird NM, (2001) The family based association test method: strategies for studying general genotype-phenotype associations. European journal of human genetics: EJHG 9: 301-306.
73. Conners CK (2000) Conners' CPT II Technical Guide and Software Manual. North Tonowanda, NY: Multi-Health Systems, Inc.
74. Forero DA, Arboleda GH, Vasquez R, Arboleda H, (2009) Candidate genes involved in neural plasticity and the risk for attention-deficit hyperactivity disorder: a meta-analysis of 8 common variants. Journal of psychiatry & neuroscience: JPN 34: 361-366.
75. Choudhry Z, Sengupta SM, Grizenko N, Fortier ME, Thakur GA, et al. (2012) LPHN3 and attention-deficit/hyperactivity disorder: interaction with maternal stress during pregnancy. Journal of child psychology and psychiatry, and allied disciplines.
76. Linnet KM, Dalsgaard S, Obel C, Wisborg K, Henriksen TB, et al. (2003) Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. The American journal of psychiatry 160: 1028-1040.
77. Linnet KM, Wisborg K, Obel C, Secher NJ, Thomsen PH, et al. (2005) Smoking during pregnancy and the risk for hyperkinetic disorder in offspring. Pediatrics 116: 462-467.
78. Obel C, Linnet KM, Henriksen TB, Rodriguez A, Jarvelin MR, et al. (2009) Smoking during pregnancy and hyperactivity-inattention in the offspring-comparing results from three Nordic cohorts. International journal of epidemiology 38: 698-705.
79. Lindblad F, Hjern A, (2010) ADHD after fetal exposure to maternal smoking. Nicotine & tobacco research: official journal of the Society for Research on Nicotine and Tobacco 12: 408-415.
80. Obel C, Olsen J, Henriksen TB, Rodriguez A, Jarvelin MR, et al. (2011) Is maternal smoking during pregnancy a risk factor for hyperkinetic disorder?-Findings from a sibling design. International journal of epidemiology 40: 338-345.
81. Thakur GA, Sengupta SM, Grizenko N, Schmitz N, Page V, et al. (2012) Maternal Smoking During Pregnancy and ADHD: A Comprehensive Clinical and Neurocognitive Characterization. Nicotine & tobacco research: official journal of the Society for Research on Nicotine and Tobacco.
82. Ernst M, Moolchan ET, Robinson ML, (2001) Behavioral and neural consequences of prenatal exposure to nicotine. Journal of the American Academy of Child and Adolescent Psychiatry 40: 630-641.
83. Wallis D, (2010) The search for biomarkers for attention deficit/hyperactivity disorder. Drug news & perspectives 23: 438-449.
84. Muller UC, Asherson P, Banaschewski T, Buitelaar JK, Ebstein RP, et al. (2011) The impact of study design and diagnostic approach in a large multi-centre ADHD study: Part 2: Dimensional measures of psychopathology and intelligence. BMC psychiatry 11: 55.